Expression analysis and clinical evaluation of kallikrein-related peptidase 10 (KLK10) in colorectal cancer
| Autor: | Dimitris Xynopoulos, Matina Patsavela, Andreas Scorilas, Marina Devetzi, Dimitris Kypraios, Niki Arnogiannaki, Dimitra K. Alexopoulou, Maroulio Talieri |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Tumor suppressor gene Colorectal cancer Gene Expression KLK10 Kaplan-Meier Estimate Biology Bioinformatics Disease-Free Survival Internal medicine medicine Biomarkers Tumor Humans RNA Messenger Survival analysis Aged Neoplasm Staging Proportional Hazards Models Aged 80 and over Univariate analysis Reverse Transcriptase Polymerase Chain Reaction Gene Expression Profiling Cancer General Medicine Kallikrein Middle Aged medicine.disease Prognosis Biomarker (medicine) Female Kallikreins Colorectal Neoplasms |
| Zdroj: | Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 32(4) |
| ISSN: | 1423-0380 |
| Popis: | Kallikrein-related peptidases (KLKs) represent a serine protease family having 15 members. KLK10 is a secreted protease with a trypsin-like activity. The function of KLK10 is poorly understood, although it has been suggested that KLK10 may function as a tumor suppressor gene. In human cancer, KLK10 gene shows organ-specific up- or down-regulation. Since KLKs are promising tumor biomarkers, the examination of KLK10 mRNA expression and its association with colorectal cancer (CRC) progression was studied using semi-quantitative PCR. One hundred and nineteen primary CRC specimens were examined for which follow-up information was available for a median period of 29 months (range, 1–104 months). KLK10 expression was found to be significantly associated with TNM stage (p = 0.028). Cox proportional hazard regression model using univariate analysis revealed for the first time that high status KLK10 expression is a significant factor for disease-free survival (DFS; p = 0.002) and overall survival (OS; p = 0.026) of patients. Kaplan–Meier survival curves demonstrated that KLK10 expression of low status is significantly associated with longer DFS (p = 0.001) as well as OS (p = 0.021), suggesting that KLK10 gene expression may be used as a marker of unfavorable prognosis for CRC. As the epigenetics of cancer are unraveled, KLK10 may represent not only a novel biomarker, but also a promising future therapeutic target for the disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink